Clinical Trial Update: INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD [Phase 2]

View source ↗

Summary

INTREPID is a Phase 2 trial evaluating IRay Plus in combination with anti-VEGF treatment for wet age-related macular degeneration. The study has completed and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• IRay Plus

Snippet

Sponsor: Oraya Therapeutics, Inc. | Conditions: AMD, Wet AMD | Phase 2 | Status: COMPLETED | Results posted: 2014-12-05